Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT05025202 Completed - Hypertension Clinical Trials

Blood Pressure and Cardiac Autonomic Adaptations to Isometric Exercise Training

Start date: January 15, 2019
Phase: N/A
Study type: Interventional

A randomized, sham-controlled intervention measuring the effects of isometric exercise training (IET) on blood pressure and cardiac autonomics. IET has been proven effective in a plethora of randomized trials, but very little research has employed a sham-controlled design. This researched involved the recruitment of 30 participants who completed a 4 week IET intervention, sham control of the IET intervention, or a non-intervention control period. Pre and post blood pressure and cardiac autonomic measures were acquired and analysed. The hypothesis of this trial was a significant effect of IET on blood pressure, with no such effects following the sham control or normal control interventions.

NCT ID: NCT05022004 Completed - Ocular Hypertension Clinical Trials

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Start date: December 20, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.

NCT ID: NCT05009004 Completed - Hypertension Clinical Trials

Digital Health for Medication Adherence Among African Americans With Hypertension

Start date: May 1, 2021
Phase: Phase 1
Study type: Interventional

The proposed Phase 1 project aims to develop and test Memento.HTN, an individually-tailored, culturallysensitive digital health intervention comprised of a provider platform and linked patient SMS system to promote medication adherence among African Americans with hypertension (HTN), a group that suffers from disproportionate HTN morbidity and mortality. Memento.HTN overcomes access barriers on the part of patients and adherence support implementation barriers on the part of healthcare teams and systems. Memento.HTN is innovative in three key ways: 1) it is the first-ever linked digital provider platform and patient SMS text system for HTN medication adherence; 2) it is culturally-tailored for African Americans with HTN; and 3) it has unique monitoring functionality allowing providers to monitor individual patient adherence, support 'new start' patients, and track group adherence rates by drug class, pill format, and patient demographics.

NCT ID: NCT05001945 Completed - Hypertension, Renal Clinical Trials

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Target-HTN
Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension

NCT ID: NCT05001711 Completed - Clinical trials for Pulmonary Hypertension

Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension

Start date: July 12, 2021
Phase: N/A
Study type: Interventional

This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.

NCT ID: NCT04994860 Completed - Clinical trials for Pulmonary Arterial Hypertension

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is: - To assess the effect of BIA 5 1058 400 mg on the pharmacokinetics (PK) of sildenafil. - To assess the effect of sildenafil on the PK of BIA 5-1058.

NCT ID: NCT04994548 Completed - Cirrhosis Clinical Trials

Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension

Start date: January 1, 2005
Phase:
Study type: Observational

Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors. However, cirrhosis might be associated with upper gastrointestinal bleeding, particularly in case of portal hypertension or coagulopathy. This study aims to assess safety, efficacy and methods to prevent potential complications in cirrhosis or portal hypertension context for esophageal endoscopic resection. This retrospective multicentric French-Belgian study includes all consecutive patients with cirrhosis or portal hypertension who underwent esophageal endoscopic resection from January 2005 to 2021.

NCT ID: NCT04994119 Completed - Clinical trials for Pulmonary Arterial Hypertension

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Start date: February 23, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is: - To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9. - To assess the effect of warfarin on the PK of BIA 5-1058.

NCT ID: NCT04992936 Completed - Hypertension Clinical Trials

Effect of an Extract From the Wine Industry on Blood Pressure (HYPERGRAPES)

HYPERGRAPES
Start date: August 26, 2021
Phase: N/A
Study type: Interventional

By-products from the wine industry pose serious problems of management, both from an economic and environmental point of view. Although traditionally the use of by-products of the wine sector has been limited to the production of biogas and energy, or its use as animal feed or agricultural fertilizer, there is greater interest in the use of these by-products as a potential source of functional ingredients. Cardiovascular diseases (CVD) are the main cause of mortality in Europe, with hypertension being one of the main CVD risk factors. It has been shown that lowering blood pressure through behavioral and pharmacological interventions significantly improves CVD. Currently, one of the most widely used pharmacological therapies to treat hypertension is based on the use of angiotensin converting enzyme (ACE) inhibitors such as Captopril or Enalapril. ACE plays a key role in arterial pressure regulation, catalyzing the production of angiotensin II, an octapeptide with potent vasoconstrictor activity. In addition, ACE catalyzes the inactivation of bradykinin, peptide with vasodilator activity. The evaluation of various potential by-products of the wine industry for the generation of functional ingredients showed that an extract from the wine industry presented beneficial effects on blood pressure in in vitro models as well as in vivo models using rats with hypertension.

NCT ID: NCT04992039 Completed - Hypertension Clinical Trials

HEARTS Package Evaluation Trial in Bangladesh

Start date: October 9, 2021
Phase: N/A
Study type: Interventional

Hypertension became the leading risk factor of death globally as well as in Bangladesh. Uncontrolled hypertension is the key challenge for the success of a hypertension control programs. According to the last national STEPS Survey in Bangladesh, hypertension control rate is only 11%. World Health Organization promoted the HEARTS technical package for the hypertension control programs to improve the control scenario. National Heart Foundation of Bangladesh is implementing a hypertension control program in selected Upazilas (sub-districts) of Bangladesh in collaboration with Non-Communicable Disease Control (NCDC) Program of Directorate General of Health Services (DGHS) and Resolve to Save Lives, USA. Proposed quasi experimental study will be conducted in collaboration with NCDC of DGHS, Resolve to Save Lives, USA and Johns Hopkins University, Baltimore with an objective of to evaluate the impact of HEARTS package on the rate of hypertension control in primary health care centers in Bangladesh. In this study equal number of hypertensive adult patients will be recruited in Upazila Health Complexes of control and intervention groups with a hypothesis of, implementation of HEARTS technical package in primary health care centers can reduce the blood pressure significantly. After obtaining informed written consent, respondents' basic demographic information, history of antihypertensive medication intake and related comorbidities will be taken. Blood pressure measurements data will be recorded also. All of these data will be collected via a secured mobile application, Simple App. Collected data will be preserved in a secured cloud based database. After six months of enrolment, and end-line data will be collected at the community setup, preferably at the home of respondents, following standard techniques of BP measurement by experienced Field Research Assistants. During whole of the study procedure, every ethical right of the participants will be preserved with an utmost priority. De-identified data will be shared with the partner organizations for further scientific analysis. This study will generate robust evidence for use of HEARTS technical packages in low-and middle-income countries, like Bangladesh, especially at low-level health facilities and provide guidance for designing and implementation of other hypertension control programs.